Search Result

Results for "

bromodomain and extraterminal (BET)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (1) Androgen Receptor (1) Apoptosis (1) Epigenetic Reader Domain (18) PROTACs (3)
By Research Areas:	Cancer (17) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (2) Neurological Disease (2)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: Fat Mass and Obesity-associated Protein (FTO)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145125

SJ995973	PROTACs	Others
SJ995973 (PROTAC) is a uniquely potent degrader of **bromodomain and extra-terminal (BET)** proteins.

HY-117286

(S)-JQ-35 TEN-010	Epigenetic Reader Domain	Cancer
(S)-JQ-35 (TEN-010) is an inhibitor of the Bromodomain and Extra-Terminal *(BET)* family bromodomain-containing proteins with potential antineoplastic activity.

HY-100015

Mivebresib Maximum Cited Publications 11 Publications Verification ABBV-075	Epigenetic Reader Domain Apoptosis	Cancer
Mivebresib (ABBV-075) is a potent and orally active **bromodomain and extraterminal domain (BET) bromodomain inhibitor. Mivebresib binds to BRD4 with a K_i** of 1.5 nM .

HY-115867

GSK852	Epigenetic Reader Domain	Cancer
GSK852 is a highly potent, second bromodomain (BD2)-selective, bromo and extra-terminal domain (BET) inhibitor (pIC₅₀ = 7.9).

HY-131061

BET bromodomain inhibitor 1	Epigenetic Reader Domain	Cancer
BET bromodomain inhibitor 1 is an orally active, selective **bromodomain and extra-terminal (BET) bromodomain inhibitor with an IC₅₀** of 2.6 nM for BRD4. BET bromodomain inhibitor 1 binds to BRD2(2), BRD3(2), BRD4(1), BRD4(2), and BRDT(2) with high affinities (K_d values of 1.3 nM, 1.0 nM, 3.0 nM, 1.6 nM, 2.1 nM, respectively). bromodomain inhibitor 1 has anti-cancer activity .

HY-150516S

BET-IN-12	Epigenetic Reader Domain	Cancer
BET-IN-12 is an orally avtive inhibitor of bromodomain and extra-terminal (BET) with an IC50 of 0.9 nM for BRD4[1].

HY-160262

AR/BET protein degrader-1	Androgen Receptor PROTACs Epigenetic Reader Domain	Cancer
AR/BET protein degrader-1 (Compound 149) is an Androgen Receptor and *BET* (bromodomain and extra-terminal domain) protein degrader that can be used in cancer research .

HY-160446

BET-IN-24	Epigenetic Reader Domain	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Bet-in-24 (example 2) is a bromodomain and extra-terminal (BET) inhibitor. BET-IN-24 can be used in the study of virology, heart failure, inflammation, central nervous system (CNS) diseases and many cancers

HY-123626

BiBET	Epigenetic Reader Domain	Cancer
BiBET is a chemical probe of BET/BRD4 and is able to bind to two bromodomains simultaneously in a bivalent and cis-binding mode .

HY-163543

Progranulin modulator-2	Epigenetic Reader Domain	Neurological Disease
Progranulin modulator-2 (compound 18A) is a bromodomain and extra-terminal domain (BET) inhibitor. Progranulin modulator-2 enhances PGRN expression by targeting members of the *BET* protein family. Progranulin modulator-2 can be used to study the role of *BET* protein in neurodevelopment, neuroplasticity and neurodegeneration .

HY-153242

GSK217	Epigenetic Reader Domain	Inflammation/Immunology
GSK217 is a potent, selective, and highly soluble bromo and extraterminal domain (BET) second bromodomain (BD2) inhibitor. GSK217 can be used for the research of oncology and immune inflammation research .

HY-100653

AZD5153 1 Publications Verification	Others	Cancer
AZD5153 (Compound 13) is a trivalent triazolpyrazine bromide domain (BRD), bromodomain and extraterminal (BET) inhibitor. AZD5153 has down-regulated c-Myc gene and tumor growth inhibition activity. AZD5153 can be used in the study of BET small molecule inhibitors .

HY-132232

GSK097	Epigenetic Reader Domain	Cancer
GSK097 is a potent and selective Inhibitor of the second bromodomain (BD2) of the bromodomain and extra-terminal domain (BET) proteins. GSK097 displays 2000-fold selective for BD2 over BD1 (BRD4 data) with >1 mg/mL solubility in FaSSIF media .

HY-124596

CD161 NKR-P1A	Epigenetic Reader Domain	Cancer
CD161 (NKR-P1A) is a potent, selective and orally bioavailable **bromodomain and extra-terminal (BET) bromodomain inhibitor with an IC₅₀**s of 28.2 nM and 7.2 nM for BRD4 BD1 and BRD4 BD2, respectively. CD161 has good anticancer activity .

HY-112789

(+)-JQ1 PA 1 Publications Verification	Epigenetic Reader Domain	Cancer
(+)-JQ1 PA is a derivative of the Bromodomain and extra-terminal *(BET)* inhibitor JQ1, with an IC₅₀ of 10.4 nM. (+)-JQ1 PA is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-161346

EBET-1055	ADC Cytotoxin Epigenetic Reader Domain	Cancer
EBET-1055 is a bromodomain and extra-terminal (BET) protein degrader (EBET) composed of a BET inhibitor (EBET-590, HY-161387), an E3 ubiquitin ligase ligand and connectors. EBET-1055 effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC). EBET-1055 also simultaneously modulates cancer-associated fibroblast (CAF) activity, upregulating all reporter gene activities in organoid co-cultures .

HY-158764

PROTAC BET Degrader-12	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BET Degrader-12 (Compound 8b) is a PROTAC degrader for bromodomain and extra-terminal domain (BET)-containing proteins, which degrades the BRD3 and BRD4 in a DCAF11-dependent manner. PROTAC BET Degrader-12 inhibits cell viability of KBM7 with a DC₅₀ of 305.2 nM. (Pink: ligand for target protein (+)-JQ-1 (HY-13030); Black: linker (HY-159077); Blue: ligand for E3 ligase (HY-159076))

HY-129201

ZEN-2759	Epigenetic Reader Domain	Cancer
ZEN-2759 is a potent *BET* (Bromodomain and Extra-Terminal Domain) inhibitor, with IC₅₀ values of 0.23, 0.08 and 0.28 μM for BRD4(BD1), BRD4(BD2), and BRD4(BD1BD2), respectively .

HY-150684

GXH-II-052	Epigenetic Reader Domain	Cancer
GXH-II-052 is a potent bivalent bromodomain and extraterminal domain (BET) inhibitor. GXH-II-052 shows binding potential for BRD4-1, BRD4-2, BRD4-T, BRDT-1, BRDT-2, BRDT-T with K_d values of 28, 9.1, 4.8, 0.6, 8.4, 2.6 nM, respectively. GXH-II-052 shows antiproliferative activity. GXH-II-052 decreases the expression of c-Myc .

HY-150683

NC-III-49-1	Epigenetic Reader Domain	Cancer
NC-III-49-1 is a potent bivalent bromodomain and extraterminal domain (BET) inhibitor. NC-III-49-1 shows binding potential for BRD4-1, BRD4-2, BRD4-T, BRDT-1, BRDT-2, BRDT-T with K_d values of 0.095, 0.32, 0.29, 0.089, 5.5, 0.058 nM, respectively. NC-III-49-1 shows antiproliferative activity. NC-III-49-1 decreases the expression of c-Myc .

BET-IN-12
BET-IN-12 is an orally avtive inhibitor of bromodomain and extra-terminal (BET) with an IC50 of 0.9 nM for BRD4[1].

Cat. No.	Product Name		Classification

HY-112789

(+)-JQ1 PA 1 Publications Verification		Alkynes
(+)-JQ1 PA is a derivative of the Bromodomain and extra-terminal *(BET)* inhibitor JQ1, with an IC₅₀ of 10.4 nM. (+)-JQ1 PA is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.